{
    "clinical_study": {
        "@rank": "126229", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Pegylated Interferon-Alfa plus ribavirin for 48 weeks"
            }, 
            {
                "arm_group_label": "Vitamins", 
                "arm_group_type": "Experimental", 
                "description": "Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness of the supplementation of\n      vitamins D and B12 in combination with Pegylated Interferon-Alfa and Ribavirin in the\n      treatment of genotype 1 chronic hepatitis C, who do not qualify to receive protease\n      inhibitor in Brazil."
        }, 
        "brief_title": "Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "RNA Virus Infections", 
            "Flaviviridae Infections", 
            "Hepatitis C", 
            "Hepatitis C, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "RNA Virus Infections", 
                "Virus Diseases", 
                "Flaviviridae Infections", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized clinical trial comparing rates of RVR, eRVR, EOT and SVR during standard\n      treatment with Pegylated Interferon-Alfa plus Ribavirin compared to the same treatment\n      supplemented with B12 and vitamin D during the treatment period.\n\n      Patients assigned to the vitamin supplementation group will receive the standard treatment\n      of Pegylated Interferon-Alfa plus Ribavirin for 48 weeks together oral Vitamin D and\n      intramuscular Vitamin B12. The control group will receive the same regimen of peguilated\n      alfainterferon plus ribavirin for 48 weeks without any vitamin supplementation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genotype 1 HCV infection confirmed a positive test for anti-HCV antibody and\n             detectable serum HCV RNA by PCR\n\n          -  Pegylated Interferon-Alfa treatment na\u00efve\n\n          -  Liver biopsy with Metavir F2 or less\n\n          -  Cognitive capacity to understand and sign the informed consent\n\n        Exclusion Criteria:\n\n          -  HBV or HIV co-infection\n\n          -  Hemoglobin level less than 10 g/dL or total neutrophil count less than 1,500/mm3 or\n             platlet count below 75,000/mm3\n\n          -  Creatinin \u2265 1.5 mg/dL\n\n          -  Severe cardiopathy\n\n          -  Pregnancy or impossibility to use birth control methods by the couple, or\n             breast-feeding\n\n          -  Conditions that, according to the investigator's judgement, preclude participation in\n             the study, including clinical, cognitive or behavioural conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "272", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120274", 
            "org_study_id": "DB12SHCV", 
            "secondary_id": "U1111-1155-6986"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamins", 
                "description": "Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vitamins", 
                "description": "Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.", 
                "intervention_name": "Vitamin B 12", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamin B 12", 
                "Hydroxocobalamin", 
                "Vitamins", 
                "Vitamin B Complex"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "RNA Virus Infections", 
            "Flaviviridae Infections", 
            "Hepatitis C", 
            "Hepatitis C, Chronic", 
            "Vitamin D", 
            "Cholecalciferol", 
            "Vitamin B 12"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": {
            "contact": {
                "email": "henriquepott@gmail.com", 
                "last_name": "Henrique Pott-Junior, Dr", 
                "phone": "11-5571-5971"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "zip": "04025-001"
                }, 
                "name": "Outpatient Clinic of Viral Hepatitis (NUPAIG)"
            }, 
            "investigator": [
                {
                    "last_name": "Henrique Pott-Junior, Dr.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jorge F Senise, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Adauto Castelo, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Clinical Trial to Assess the Effectiveness of Vitamin D and Vitamin B12 Supplementation in Combination With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C.", 
        "overall_contact": {
            "email": "henriquepott@gmail.com", 
            "last_name": "Henrique Pott-Junior, Dr"
        }, 
        "overall_official": [
            {
                "affiliation": "Federal University of S\u00e3o Paulo", 
                "last_name": "Adauto Castelo, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Federal University of S\u00e3o Paulo", 
                "last_name": "Jorge F Senise, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients with SVR, defined as HCV RNA bellow the limit of detection 12 weeks after treatment completion with peguilated alfainterferon-2B plus ribavirin, with or without vitamin supplementation.", 
            "measure": "SVR12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after treatment completion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120274"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of S\u00e3o Paulo", 
            "investigator_full_name": "Henrique Pott Junior", 
            "investigator_title": "Dr. Henrique Pott-Junior", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Proportion of patients presenting HCV RNA bellow the limit of detection at week 4 (RVR), week 12 (EVR - early virological response) and at the end-of-treatment (EOT);", 
            "measure": "RVR, EVR, EOT", 
            "safety_issue": "No", 
            "time_frame": "week 4, week 12 and at the end-of-treatment."
        }, 
        "source": "Federal University of S\u00e3o Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federal University of S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}